



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/61

Date: 17th December 2025

To,

The Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: **Updates on incorporation Sudarshan Pharma Poland Limited Liability Company, Poland**
Ref: **Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In continuation of the Company's disclosure dated 19th February 2025 (SPIL/CS/SE/2024-25/65), regarding approval of the Board to incorporate a Limited Liability Company in Poland as a wholly-owned subsidiary of the Company (referred to as '**Sudarshan Poland**'), pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('**SEBI Listing Regulations**'), this is to inform you that Sudarshan Poland has been incorporated as a wholly-owned subsidiary having service address in Bartycka, number 22B, room 21A, postal code 00-716, Warsaw, Poland.

The Company has subscribed to 100 shares of Polish zloty 50 each (currency of Poland 'PLN') of Sudarshan Poland aggregating to PLN 5,000 (approx. Rs.1,30,000/-) (100.00% of the paid-up share capital).

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure-A.

This is for your information and record.

Thanks & Regards,

For, Sudarshan Pharma Industries Limited

Sachin Mehta
Joint Managing Director &
Chief Financial Officer



Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

Annexure - A

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

Sr. no.	Details to be provided	Detailed Information
1	Name of the target entity, details in brief such as size, turnover etc.	SUDARSHAN PHARMA POLAND LIMITED LIABILITY COMPANY Turnover: Not applicable since it is a newly incorporated Company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	Not Applicable as Sudarshan Poland is incorporated as a wholly-owned subsidiary of the Company and the Company has subscribed to 100 shares of PLN 50 each (100.00% of the subscribed capital of Sudarshan Poland.
3	Industry to which the entity being acquired belongs;	The main object of Sudarshan Poland is manufacture of basic chemicals, fertilizers and nitrogen compounds, plastics and synthetic rubber in primary forms.
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the Company)	Sudarshan Poland will enable the Company to enlarge its customer base in the European region.
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Sudarshan Poland is incorporated and shall be governed as per the laws of Poland.
6	Indicative time period for completion of the acquisition	Not applicable
7	Consideration - whether cash consideration or share swap or any other form and details of the same	The Company shall acquire the subscribed shares in cash and the same shall be remitted after obtaining necessary approval from the Reserve Bank of India.
8	Cost of acquisition and/or the price at which the shares are acquired;	The Company has subscribed to 100 shares of Polish zloty 50 each (currency of Poland 'PLN') of Sudarshan Poland aggregating to PLN 5,000 (approx. Rs.1,30,000/-) (100.00% of the paid-up share capital)





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

9	% of shareholding control acquired and / or number of shares acquired	100% of the paid-up share capital of Sudarshan Poland is held by the Company.
10	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>The main object of Sudarshan Poland is manufacture of basic chemicals, fertilizers and nitrogen compounds, plastics and synthetic rubber in primary forms. The other objects of Sudarshan Poland include:</p> <ol style="list-style-type: none">1) Manufacture of pesticides, disinfectants and other agrochemical products2) Manufacture of soap and detergents, washing and polishing preparations3) Manufacture of other chemical products, not elsewhere classified4) Wholesale of perfumes and cosmetics5) Wholesale of pharmaceutical and medical

For, Sudarshan Pharma Industries Limited

Sachin Mehta
Joint Managing Director &
Chief Financial Officer

